Key result
Transcatheter valve-in-valve replacement is contraindicated in patients with patient-prosthesis mismatch as it leads to poor outcomes and early prosthetic degeneration.
Patient-prosthesis mismatch should be recognized as a contraindication for transcatheter valve-in-valve mitral valve replacement.
Severe mitral annular calcification (MAC) may represent a challenging issue which can lead to poor outcomes and serious issues such as patient-prosthesis mismatch (PPM). The potential harmful effect of PPM must be prevented through the use of alternative techniques that allow mitral valve replacement with adequately sized bioprostheses in patients with MAC. PPM should be recognized as a contraindication for transcatheter valve-in-valve replacement as it leads to poor outcomes and early prosthetic degeneration.
No takes yet. Share an insight, caveat, or question.
Marin‐Cuartas et al. (2020) conducted an editorial in Severe mitral annular calcification (MAC) and patient-prosthesis mismatch (PPM). Transcatheter valve-in-valve replacement was evaluated. Transcatheter valve-in-valve replacement is contraindicated in patients with patient-prosthesis mismatch as it leads to poor outcomes and early prosthetic degeneration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: